Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document LNA043 - ANGPTL3 agonist Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic > Immunology Neuroscience Oncology Other Global Health Abbreviations References NCT04864392 ONWARDS (CLNA043A12202) Knee osteoarthritis Indication Phase Phase 2 Patients 550 Primary Outcome Measures Arms Intervention Change from baseline in the cartilage thickness of the medial compartment of the knee as assessed by imaging LNA043 injection to the knee with dosing regimen A LNA043 injection to the knee with dosing regimen B LNA043 injection to the knee with dosing regimen C LNA043 injection to the knee with dosing regimen D Placebo injection to the knee Patients with Symptomatic knee osteoarthritis Primary 2024 Target Patients Readout Milestone(s) Publication TBD □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 62

View entire presentation